Catheter-based edge-to-edge repair may provide benefit, according to results from a preliminary single-arm trial.
Tricuspid regurgitation (TR), a common form of valvular heart disease, frequently results from right ventricular dilatation and leaflet tethering, leading to malcoaptation of the leaflets. TR has been associated with poor long-term survival and with impaired response to correction of left-sided cardiac pathology. Nonetheless, surgical correction of TR is rarely performed, and the tricuspid valve is often described as the “forgotten valve.” To address this therapeutic challenge, device manufacturers are developing percutaneous approaches to tricuspid valve repair.
Código de aprobación: PP-CVP-PEB-0015
Portal web de Pfizer para Profesionales, donde podrá acceder a una amplia variedad de contenidos y servicios tales como:
Confirmo que soy profesional de la salud residente en Perú.
Si no es profesional de la salud consulte
www.pfizer.com.pe